Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epoch and Specialty Labs to develop assays:

This article was originally published in Clinica

Executive Summary

Genomic and molecular diagnostics company Epoch Biosciences and Specialty laboratories, a specialised medical testing service, are to jointly develop highly sensitive assays to determine whether abnormal cells remain in the bloodstream following treatment to eradicate leukaemia. Redmond, Washington-based Epoch will develop probes for the assays, while Specialty, of Santa Monica, California, will develop and clinically evaluate the assays. It will also offer them commercially under a licence granted by Epoch.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT076157

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel